NASDAQ · AXSM
Axsome Therapeutics, Inc.
$140.00-$3.45 (-2.41%)
Axsome Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.19% below the high.
Loading market information…
NASDAQ · SAVAW · USD
Stock price
Quote as of Aug 19, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cassava Sciences, Inc. Warrant’s quoted price sits in the lower half of its reported 52-week range, 99.73% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Cassava Sciences, Inc. is a biotechnology firm currently in the clinical development stage, dedicated to discovering therapies for neurodegenerative disorders. Their key therapeutic asset is simufilam, a small molecule drug that has already completed its Phase 2b clinical evaluation. Furthermore, the company is advancing SavaDx, a diagnostic tool utilizing blood-based biomarkers for the early detection of Alzheimer's disease. Incorporated in 1998, the organization was previously known as Pain Therapeutics, Inc. until its name change to Cassava Sciences, Inc. in March 2019. The company's headquarters are located in Austin, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:50 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$140.00-$3.45 (-2.41%)
Axsome Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.19% below the high.
$43.52-$0.10 (-0.24%)
Ethos Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
$10.59-$0.28 (-2.57%)
Monte Rosa Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.9% below the high.
$4.47-$0.10 (-2.08%)
Abeona Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.63% below the high.
$1.64-$0.03 (-1.8%)
Inhibikase Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.16% below the high.
$1.97-$0.09 (-4.37%)
TuHURA Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.57% below the high.
$1.26-$0.05 (-3.46%)
Anavex Life Sciences Corp.’s quoted price sits in the lower half of its reported 52-week range, 84.58% below the high.
$1.04+$0.01 (+1.47%)
Annovis Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.18% below the high.
